Study on the duration of effect of venetoclax/venetoclax on platelet function

Venetoclax, trade name Venclexta, has been widely used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). This drug exerts its effect by binding directly to the B-cell lymphoma-2 (BCL-2) protein. BCL-2 is a protein that plays a key role in cell life and death decisions. The binding of venetoclax to BCL-2 causes other key proteins, such as BIM, to be replaced, which in turn activates the process of apoptosis, a type of programmed cell death.

In cancers such as CLL, SLL and AML, cancer cells overexpress BCL-2, meaning they contain much more of this protein than normal cells. Venetoclax can effectively kill these cancer cells by blocking or inhibiting the function of BCL-2. Although venetoclax is primarily classified as a BCL-2 inhibitor, it is also considered a drug with anti-tumor or targeted therapy properties.

It is important to note that venetoclax's effects on platelets are not central to its treatment. Platelets are a key component of blood and play a vital role in hemostasis and thrombosis. Although venetoclax may have some effect on platelets during treatment, this is not the primary basis for evaluating its therapeutic effect.

Venetoclax may cause side effects including thrombocytopenia during treatment. In order to ensure patient safety, doctors will regularly monitor the patient's platelet count and function and make appropriate treatment adjustments based on the patient's specific condition. Once the platelet count drops to dangerous levels, doctors may take measures such as blood transfusions or other medications to increase the platelet count to ensure the health and safety of the patient.